Table 1.
Characteristics of patients and tumor samples.
| Characteristics | (Total) | Number of Samples | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Residual tumor 1 | (108) | R0 | 17 | R1 | 27 | R2 | 21 | R3 | 43 |
| CHT response (acc. to RECIST) 2 | (108) | CR | 74 | PR | 31 | NC | 1 | P | 2 |
| Histopathological type | (108) | serous | 97 | undifferentiated | 10 | other | 1 | ||
| Tumor grade | (108) | G2 | 2 | G3 | 76 | G4 * | 30 | ||
| Platinum sensitivity 3 | (108) | Highly sensitive | 22 | Moderately sensitive | 42 | Resistant | 44 | ||
| TP53 accumulation | (108) | Yes | 68 | No | 40 | ||||
| Age | (108) | ≤54 years | 56 | >54 years | 52 | ||||
1 Residual tumor size: R0 = 0 cm, R1 < 0.5 cm, R2—between 0.5 cm and 2 cm, R2 ≥ 2 cm; 2 Chemotherapy (CHT) response, described as clinical status of the patient after first-line treatment: CR—complete response, PR—partial response, NC—no change, P—progression; RECIST—Response Evaluation Criteria in Solid Tumors; 3 Tumors were classified as highly sensitive when disease free survival (DFS) > 732 days, moderately sensitive when 732 days > DFS > 180 days, and resistant when DFS < 180 days *—classification criteria given by Barber [26].